ClinicalTrials.gg
WithdrawnNCT07172867Updated Feb 25, 2026

A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM

A Phase 2 interventional study of HT-6184 and HT-6184 Matching Placebo in Diabetes Mellitus, Type 2 and Obesity, sponsored by Halia Therapeutics, Inc.. Withdrawn at 1 site in United Arab Emirates. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Halia Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Business decision to move away from this indication with this intervention, and low enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Diabetes Mellitus, Type 2 with a site in United Arab Emirates — 3 open to participants now, 4 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · United Arab Emirates.

Enrollment
24th of 24
0 · median 339
Started
2026
with 1 other
Phase 2
2 of 40
none open now
Registered
39th of 40
by date
Lead sponsor
1 of 40
Halia Therapeutics, Inc.

Among the 40 studies in Diabetes Mellitus, Type 2 with a site in United Arab Emirates, this one is the 24th largest by enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2026, is one of 2 in phase 2, and was the 39th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 40 studies in Diabetes Mellitus, Type 2 with a site in United Arab Emirates are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United Arab Emirates have not opened yet or have stopped. Only those recruiting at a site in United Arab Emirates →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Diabetes Mellitus, Type 2 with a site in United Arab Emirates, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of ofirnoflast in combination with semaglutide in comparison to semaglutide alone in obese participants with T2DM.

Read the detailed description

The purpose of this study is to evaluate the efficacy and safety of ofirnoflast in combination with semaglutide in comparison to semaglutide alone in obese participants with T2DM.

This study is a randomized, double-blind, placebo-controlled, parallel-group clinical trial.

  • The study duration will be up to 28 weeks.
  • The screening period will be up to 4 weeks
  • The treatment duration will be 12 weeks.
  • The follow-up period will be 12 weeks
  • The visit frequency will be every 4 weeks during the treatment phase of the study.
  • There will be an anticipated 7 scheduled clinic visits, including 1 screening visit and 2 follow-up visits.
03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Obesity
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 65 years of age inclusive, at the time of signing the .
  • Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
  • between 27 kg/m2 and 40 kg/m2.
  • Stable body weight (± 5 kg) within 90 days of screening, and body weight \<150 kg.
  • is 7.5-10.5% at screening.
  • Established diagnosis of T2DM.
  • Receiving a stable 1mg SC q1wk dose of semaglutide (Ozempic®) for ≥ 90 days prior to signing informed consent.
  • Females must meet one of the following:

    1. (>45 years of age with amenorrhea for at least 12 months, without using exogenous hormonal and with FSH ≥ 40 IU/L).
    2. Surgically sterile (hysterectomy, bilateral salpingectomy; oophorectomy) for at least 6 months.
    3. Using a double contraception including a barrier method (condom, diaphragm, or occlusive cap) and a highly effective method of birth control, which includes the following:

    i. Established use (i.e. at least 90 days prior to signing of ICF) of combined (estrogen and progestogen) oral, intravaginal, or transdermal hormonal contraceptive associated with inhibition of ovulation ii. Established use (i.e. at least 90 days prior to signing of ICF) of progestogen-only oral, injectable, or implantable hormonal contraceptive associated with inhibition of ovulation iii. Established use (i.e. at least 90 days prior to signing of ICF) of an intrauterine device (IUD) or intrauterine hormone-releasing system (IUS) iv. Bilateral tubal occlusion completed at least 90 days prior to signing of ICF d. Vasectomized partner with the appropriate post-vasectomy documentation of the absence of spermatozoa in the ejaculate. Participant must provide documentation before the first dose of ofirnoflast (study day 1).

    e. Sexual abstinence, when this is in line with the preferred and usual lifestyle of the participant

  • Male participants who are sexually active with a woman of must agree to use a double contraception including a barrier method (male condom) and a highly effective method of contraception (highly effective methods of contraception are listed above) during the study and for 30 days after the last dose of ofirnoflast/ placebo.
  • In the case of WOCBP, participants must have a negative serum pregnancy test (β-human chorionic gonadotropin [β-hCG]) at screening and negative urine pregnancy tests on first day of dosing and at each study visit.
  • Able to comply with the study procedures in the view of the Investigator.

Exclusion criteria

Exclusion Criteria:

  • Any prescription or over-the-counter medications intended for weight loss within 6 months of screening, excluding semaglutide.
  • History of, or known to, monoclonal antibody drugs or a to semaglutide (e.g. Ozempic® or Wegovy®)
  • Use of other drugs at the time of screening or within 30 days or 5 half-lives prior to signing of the ICF, whichever is longer, or longer if required by local regulations
  • Previous or current diagnosis of Type 1 diabetes mellitus (T1DM) or current gestational diabetes.
  • Diagnosis of T2DM requiring current use of insulin, repaglinide, saxagliptin, and sulfonylureas.

Note. Use of Metformin for the purposes of glycemic control is not exclusionary.

  • History of diabetic ketoacidosis (within 90 days of screening), or proliferative or severe retinopathy (i.e., retinopathy requiring acute treatment).
  • Previous bariatric surgery, liposuction, or planned weight loss surgery.
  • Current or past diagnosis of pancreatitis
  • Current or past diagnosis of severe gastroparesis
  • Personal or within first-degree relative family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
  • Calcitonin ≥20 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened)
  • Laboratory abnormalities at screening
  • Current or history of (per Investigator's judgment) liver or biliary disease or significantly abnormal LFT at screening (see above)
  • Current acute or chronic self-reported and/or infection
  • Current or history of clinically significant renal disease (per Investigator's judgment) or \<60mL/min/1.73m2
  • Prior history of (including breast cancer, lymphoma, leukemia) within the past 5 years except for cervical carcinoma in situ that has been completely resected with no evidence of recurrence or disease for at least 12 months or cured basal cell carcinoma with no evidence of recurrence for at least 12 months.
  • History of a major organ transplant (e.g. kidney, heart, liver, lung) or hematopoietic stem cell/ bone marrow transplant.
  • History of lymphoproliferative disease or signs/ symptoms suggestive of possible lymphoproliferative disease, including splenomegaly of lymphadenopathy.
  • History or current moderate to severe congestive heart failure ( class III or IV), or within the last 6 months, a cerebrovascular accident, myocardial infarction, unstable angina, unstable arrhythmia or any other cardiovascular condition which, in the opinion of the Investigator, would put the participant at risk by participation in the study.
  • Undergone any major surgery within 8 weeks prior to study entry or will require major surgery during the study that, in the opinion of the Investigator, would pose an unacceptable risk to the participant.
  • Planning elective surgery during the study duration
  • Inherited or acquired thrombophilia and/ or current or history of thromboembolic events/ disease.
  • Screening 12-lead that demonstrates relevant abnormalities that, in the opinion of the Investigator, are clinically significant and indicate an unacceptable risk for the participant's participation in the study (e.g., >450 msec or a QRS interval >120 msec). If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTc or QRS values should be used to determine the participant's eligibility.
  • History or evidence of any other clinically significant concomitant disorder, condition or disease that, according to the Investigator's and medical monitor's (if consulted) judgment, would pose a risk to participant safety or interfere with the study evaluation, procedures, completion or interpretation of data
  • Pregnant or breast-feeding.
  • Blood donation within the last month before study day 1 (first dose of ofirnoflast or placebo)
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    HT-6184 2mg Treatment

    Ofirnoflast (2 mg): dosed once a day, orally (PO QD) + semaglutide (1 mg): dosed weekly (q1wk), via subcutaneous (SC) injection for 12 weeks.

    Drug: HT-6184 · Drug: Semaglutide 1 mg

  • Placebo comparator
    HT-6184 2mg Matching Placebo

    Placebo: dosed once a day, orally (PO QD) + semaglutide (1 mg): dosed weekly (q1wk), via SC injection for 12 weeks.

    Drug: HT-6184 Matching Placebo · Drug: Semaglutide 1 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Assess glycemic control using HbA1c (%)

    Evaluate glycemic control using HbA1c (%) from baseline to week 12 in participants treated with ofirnoflast or placebo in combination with semaglutide. This outcome will assess if the participant was able to reduce HbA1c by at least 1.5%.

    Time frame: From first dose through End of Study (up to 12 weeks per participant)

  2. Assess weight loss using body weight measurements

    Evaluate weight loss using body weight measurements from baseline to week 12 in participants treated with ofirnoflast or placebo in combination with semaglutide. This outcome will assess if the participant was able to reduce body weight by at least 5%.

    Time frame: From first dose through End of Study (up to 12 weeks per participant)

Secondary outcomes

  1. Assess the change in HbA1c (% point)

    Evaluate the change in HbA1c (% point) from baseline to week 12 in participants treated with ofirnoflast or placebo in combination with semaglutide.

    Time frame: From first dose through End of Study (up to 12 weeks per participant)

  2. Assess the change in body composition utilizing DEXA body scan

    Evaluate the change in body composition utilizing DEXA body scan from baseline to week 12 in participants treated with ofirnoflast or placebo in combination with semaglutide.

    Time frame: From first dose through End of Study (up to 12 weeks per participant)

  3. Assess the PK profile; AUC 0-inf, AUC 0-last, AUC tau, Cmax, tmax, t1/2, and Cl/F

    Evaluate the PK profile (AUC 0-inf, AUC 0-last, AUC tau, Cmax, tmax, t1/2, and Cl/F) of ofirnoflast in participants treated with ofirnoflast and semaglutide

    Time frame: From first dose through End of Study (up to 12 weeks per participant)

  4. Assess number of participants who experience Serious Adverse Events (SAEs)

    The safety and tolerability of ofirnoflast or placebo in combination with semaglutide will be evaluated based on the incidence of SAE in participants, as assessed according to CTCAE v5.0. The number of participants who experience a SAE will be reported.

    Time frame: From first dose through End of Study (up to 12 weeks per participant)

  5. Assess number of participants who experience treatment emergent adverse events (TEAEs)

    The safety and tolerability of ofirnoflast or placebo in combination with semaglutide will be evaluated based on the incidence of TEAE in participants, as assessed according to CTCAE v5.0. The number of participants who experience a TEAEs will be reported.

    Time frame: From first dose through End of Study (up to 12 weeks per participant)

  6. Assess number of participants who experience treatment related adverse events (TRAEs)

    The safety and tolerability of ofirnoflast or placebo in combination with semaglutide will be evaluated based on the incidence of TRAEs in participants, as assessed according to CTCAE v5.0. The number of participants who experience a TRAEs will be reported.

    Time frame: From first dose through End of Study (up to 12 weeks per participant)

07

Study locations

1 site
  • Cleveland Clinic Abu Dhabi
    Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2026 to primary completion in Jan 2026, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2025
First posted
Sep 15, 2025
StartActual
Jan 6, 2026
Primary completionActual
Jan 23, 2026
CompletionActual
Jan 23, 2026
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07172867
Lead sponsor
Halia Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 15, 2025
Start date
Jan 6, 2026
Primary completion
Jan 23, 2026
Completion
Jan 23, 2026
Last update
Feb 25, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ofirnoflast

Start the discussion